Prognostic variables in node-negative and node-positive breast cancer Cover

Prognostic variables in node-negative and node-positive breast cancer

ISBN/ASIN: 9781461373667,9781461551959 | 1998 | English | pdf | 428/415 pages | 13.3 Mb
Publisher: Springer US | Author: Giampietro Gasparini (auth.), Giampietro Gasparini (eds.) | Edition: 1

Prognostic variables in node-negative and node-positive breast cancer – Introduction; G. Gasparini. Routinely available indicators of prognosis in breast cancer; D.L. Page, et al. Prognostic factors for patients with breast cancers 1cm and smaller; Y.-Y. Chen, S.J.Schnitt. Steroid hormone receptors in breast cancer management; C.K.Osborne. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer; J. Bryant, et al. S-phase fraction and breast cancer – a decade of experience; C.R.Wenger, G.M. Clark. Prognostic and predictive value of thymidine labelling index in breast cancer; D. Amadori, R. Silvestrini. Cyclin D1 in breast cancer; D.M. Barnes, C.E. Gillett. Cyclins and breast cancer; P.S. Steeg, Q. Zhou. Prognostic implications of expression of the cell cycle inhibitor p27Kip1; S. Cariou, et al. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer; W.J. Gullick, R. Srinivasan. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients; S. De Placido,et al. HER-2/neu as a predictive marker of response to breast cancer therapy; M.D. Pegram, et al. Prognostic and predictive value of p53 and p21 in breast cancer; R.M. Elledge. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer; R.W. Stephens, et al. Metalloproteinases and tissue inhibitors of metalloproteinases; M. Toi, et al. Matrix metalloproteinase inhibitors; P.D. Brown. The 67 kDa laminin receptor as a prognostic factor in human cancer; S. Ménard, et al. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis; R. Heimann, et al. Clinical significance of angiogenic factors in breast cancer; N. Locopo. Insulin-like growth factors in human breast cancer; M.J. Ellis, et al. Molecular prognostic markers in breast cancer; R. Dahiya, G. Deng. Prognostic significance of micrometastatic bone marrow involvement; S. Braun, K. Pantel. Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis; I. Jatoi. Time-dependence of hazard ratios for prognostic factors in primary breast cancer; S.G. Hilsenbeck, et al. Circulating tumors markers in breast cancer. Accepted utilities and novel prospects; V. Stearns, et al. The relationship between prognostic and predictive factors in the management of breast cancer; I.C. Henderson, A.J. Patek. Methodological challenges in the evaluation of prognostic factors in breast cancer; D.G. Altman, G.H.Lyman. Assessing the clinical impact of prognostic factors: When is `statistically significant' clinically useful? D.F. Hayes, et al. Prognostic variables in node-negative and node-positive breast cancer &endash; editorial; G. Gasparini. Author index. Subject index.

Prognostic variables in node-negative and node-positive breast cancer

Category: Uncategorized